Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication
- 145 Downloads
This study assessed the clinical usefulness of a new technetium-99m labelled somatostatin analogue from the standpoint of oncological diagnostics. The study group comprised 40 patients in whom malignant neoplasms (32 primary and 8 metastatic) had been diagnosed. Among the primary tumours there were 21 cases of lung cancer (2 small cell and 19 non-small cell), seven pituitary adenomas (five hormonally active and two inactive), one liposarcoma, two carcinoids and one breast carcinoma. The metastatic tumours consisted of three malignant melanomas, one phaeochromocytoma, one prostatic cancer, one leiomyosarcoma, one pancreatic carcinoma ectopically secreting ACTH and one carcinoid of the thymus. The radiopharmaceutical 99mTc-EDDA/HYNIC-Tyr3-octreotide was administered i.v. at an activity of 740–925 MBq. The imaging comprised a whole-body scan and a single-photon emission tomography acquisition. Positive scintigrams were obtained in all cases of small cell and non-small cell lung cancer, four out of five hormonally active pituitary adenomas, one out of two cases of carcinoid, the liposarcoma and the breast cancer. Neoplastic metastases were visualised in two out of three patients with melanoma and in patients with phaeochromocytoma, ACTH-secreting pancreatic carcinoma and thymic carcinoid. Scintigrams were negative in both hormonally inactive pituitary adenomas, in one case of metastatic malignant melanoma, in the leiomyosarcoma and in the case of metastasis from prostatic carcinoma. The results of this pilot study indicate that 99mTc-EDDA/HYNIC-TOC is a potentially useful radiopharmaceutical for imaging of a wide range of primary and metastatic tumours. Special attention should be paid to the successful imaging of all cases of non-small cell lung cancer .
KeywordsSomatostatin analogue Receptor scintigraphy Tumour targeting Octreotide Lung cancer
This study was supported in part by COST ACTION B 12 "Radiotracers for in vivo assessment of biological function", Working Group 3 "Radiolabelled biologically active peptides".
- 1.Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooji PPM, Oei HY, van Hagen M, Postema PTE, de Jong M, Reubi JC, Visser TJ, Reijs AEM, Hofland LJ Koper JW., Lamberts SWJ. Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20:716–731.PubMedGoogle Scholar
- 6.Maecke HR, Béhé M. New octreotide derivatives labelled with technetium-99m [abstract]. J Nucl Med 1996; 37:1144.Google Scholar
- 8.Decristoforo C, Mather SJ, Cholewinski W, Donnemiller E, Riccabona G, Moncayo R.99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med 2000; 27:1318–1325.PubMedGoogle Scholar
- 11.Kwekkeboom DJ, Kho GS, Lamberts SWJ, Reubi CJ, Laissue JA, Krenning EP. The value of octrotide scintigraphy in patients with lung cancer. Eur J Nucl Med 1994; 21:1106–1113.Google Scholar